Rasio rega marang bathi Lucid Diagnostics, Inc (LUCD)

Lucid Diagnostics Inc. (LUCD) generates revenue from the diagnosis of precancerous esophageal pathologies by offering EsoGuard tests to gastroenterologists and individuals with GERD. New Medicare codes and the expansion of specialized center networks support business growth. The price history on GURU.Markets, where the indicator stands at -1.20, confirms the resilience of a business protected by FDA patents and the inclusion of its methodologies in official medical protocols.

LUCD Lucid Diagnostics: Rasio rega marang bathi ing interval 22.08.2022 - 11.11.2026

Rincian analitis perusahaan Lucid Diagnostics Inc.

- rega lan prakiraan konsensus rega:

Rega saham luciddx.com|LUCD - Bagan rega target

- rincian kapitalisasi pasar:

Nilai pasar Lucid Diagnostics Inc.|LUCD - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- informasi kapitalisasi buku:

Nilai Aset Bersih saben Saham Lucid Diagnostics|LUCD - Nilai Buku Perusahaan|Kapitalisasi Pasar marang Nilai Buku luciddx.com|LUCD - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Koefisien Total Utang marang Modal Lucid Diagnostics Inc.|LUCD - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal Lucid Diagnostics, Inc|LUCD - Utang perusahaan|Rasio utang marang kapitalisasi buku Lucid Diagnostics Inc.|LUCD - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Lucid Diagnostics|Indikator likuiditas cepet luciddx.com

- data bathi bisnis lan rasio investasi:

LUCD - Bathi resik|Prakiraan bathi perusahaan Lucid Diagnostics Inc.|LUCD - Pangali P/E|Rasio rega marang bathi mangsa ngarep Lucid Diagnostics, Inc.|LUCD - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Lucid Diagnostics Inc.|LUCD - Bathi operasional EBITDA|Bathi saben saham sajrone 12 wulan pungkasan Lucid Diagnostics|LUCD - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan luciddx.com|LUCD - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lucid Diagnostics Inc.

Analisis komprehensif perusahaan:luciddx.com

Produk asil prodhuksi Lucid Diagnostics Inc.

Lucid Diagnostics Inc. (LUCD) is transforming esophageal cancer diagnostics through its non-invasive EsoGuard test, which serves as a replacement for endoscopy. The P/E ratio quantifies the value of this technological advantage by comparing the market price of the stock with the net earnings per share. By analyzing the company's historical P/E levels, an investor can determine the extent of the premium paid for future earnings growth. Low values minimize the risk of a correction, yet they may signal market skepticism regarding the scalability of these innovations.

Perusahaan pesaing